NAVERIS

NAVERIS was founded on the belief that advanced diagnostics, such as NavDx, have the power to enable curative outcomes for many cancer patients with the therapies already available to us today—a premise that has been validated in clinical practice since we made our test available to physicians in 2020. I'm thrilled that the American Society for Radiation Oncology (ASTRO) has spotlighted the pivotal role of innovative biomarkers in advancing cancer medicine. Read more in the latest ASTROnews online edition about how innovative biomarkers are shaping the future of cancer care in radiation oncology.

If you’re a healthcare professional looking to incorporate the NavDx? blood test into your cancer surveillance protocol, register for our Provider Portal. The NavDx provider portal can be used to order testing for your patients, streamline the ordering process, gain real-time access to your patients’ longitudinal test results, and more. Register today: https://lnkd.in/eCeBYCFq #HCPtools #healthcare #providerportal

ICYMI, Naveris founder Piyush Gupta, PhD participated in an important panel discussion last week focused on trends in HPV-driven cancers. If you were not able to attend, you can register for on-demand viewing: https://lnkd.in/exBJRQTt In HPV-driven head & neck, and anal cancer surveillance, routine NavDx? testing of the TTMV?-HPV DNA biomarker is helping physicians optimize HPV+ cancer care for their patients. Help us continue to drive #HPVAwareness and be a part of creating a better future for those affected by HPV-driven cancer. #HPVawarenessday #healthcarepanel #CancerPrevention

In case you haven't seen it, the Winter edition of News from American Society for Radiation Oncology (ASTRO) features information on the role of biomarkers in radiation oncology. As a team focused on both biomarkers and improved surveillance testing for patients and HCPs in the world of HPV-driven cancers, we were very interested in what ASTRONews had to say - especially around the use of circulating tumor HPV DNA (ctHPVDNA) as a biomarker in the post-radiation treatment surveillance setting. In line with what we have seen, Dr. Riaz and Dr. Chera comment on biomarkers for head and neck cancer, specifically saying "Here, a positive ctHPVDNA test often indicates a high risk of recurrence, necessitating closer surveillance. Although not yet included in consensus guidelines, some routinely incorporate ctHPVDNA in this setting. Data suggest that recurrence can be detected in an early state with this approach." For more detail on biomarkers and surveillance approaches, visit ASTRONews to view the flipbook: https://lnkd.in/ePR22GHY #research #clinicaldata #oncology #healthcarenews

This #HPVAwarenessDay, take action by joining experts in a discussion about tackling HPV challenges and innovations. Naveris? founder Piyush Gupta, PhD will be joining QIAGEN and other HPV thought leaders for a round table event to discuss important aspects of HPV-related cancer care. Join us at 4:00am EST (GMT -5) on March 4th to: ● Explore challenges in HPV screening and surveillance. ● Understand HPV’s impact on multiple cancers. ● Discover early detection breakthroughs from experts. ● Engage in an interactive Q&A session. Register now for the live roundtable or replay: https://lnkd.in/eTRsQdKb #HPVawarenessday #healthcarepanel #CancerPrevention

Did you know? Chronic infection with high-risk types of human papillomavirus (HPV) leads to nearly 37,800 cases of cancer in the US every year (source: https://lnkd.in/eZh-4K7Y). HPV-associated cancer is typically diagnosed in areas of the body where HPV is often found. The three most common types of HPV-associated cancer are head & neck, cervical, and anal cancer. If you've been impacted by HPV, be sure to discuss how this might impact your cancer risk with your healthcare provider. Learn more about HPV-related cancers and how NavDx testing is helping to optimize care: https://lnkd.in/esSeHwtt #HPV #oncology #cancer #healthcare

JOIN US: Our founder Piyush Gupta, PhD along with QIAGEN and other HPV thought leaders will participate in a round table on International HPV Awareness Day. Topics will include: ● Explore challenges and opportunities in HPV screening and surveillance ● Discover innovations shaping the future of early detection ● Q&A: Get your questions answered by leading experts. Register now to join the conversation on March 4, 2025: https://lnkd.in/eTRsQdKb Experts discuss breaking barriers in HPV understanding, prevention and surveillance to create a healthier future for everyone. #HPVawarenessday #healthcarepanel #CancerPrevention

After treatment, regular monitoring with the NavDx? blood test can help detect recurrence earlier than imaging, biopsies, or physical exam - but it's important to talk to your doctor about how to work the NavDx test into your surveillance plan. Visit the Patient Resources section of the NavDx.com website to download and customize your own discussion guide and help prepare you for a conversation with your provider. https://lnkd.in/eepWreQw #HPVcancer #doctordiscussionguide #careteam

We’re #hiring a new Salesforce Full-Stack Developer in Waltham, Massachusetts. Apply today or share this post with your network.

ICYMI: We have added HPV-positive anal cancer surveillance testing to the list of cancer types that can be monitored by our innovative NavDx? blood test. Anal cancer is an especially challenging cancer to monitor for recurrence but utilizing routine NavDx surveillance testing can be an important part of post-treatment care. Learn more: https://lnkd.in/eUqmTyG5 #oncologynews #analcancer #healthcare